Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael D. Ezekowitz

Showing results (121-130 of 187) with videos related to

Pageof 19
Sort By:
Open Heart|March 20, 2021
Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areasTymon Pol, Ziad Hijazi, Johan Lindbäck, et al.
Stroke|February 3, 2009
Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigatorsCarl van Walraven, Robert G Hart, Stuart Connolly, et al.
Journal of the American College of Cardiology|June 13, 2015
Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY TrialMichael Böhm, Michael D Ezekowitz, Stuart J Connolly, et al.
Circulation. Arrhythmia and Electrophysiology|May 27, 2022
Drug Interactions Affecting Oral Anticoagulant UsePhilip L Mar, Rakesh Gopinathannair, Brooke E Gengler, et al.
Journal of the American College of Cardiology|February 18, 2011
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelinesL Samuel Wann, Anne B Curtis, Kenneth A Ellenbogen, et al.
Circulation|March 8, 2013
Genetic determinants of dabigatran plasma levels and their relation to bleedingGuillaume Paré, Niclas Eriksson, Thorsten Lehr, et al.
European Heart Journal|June 4, 2024
Emergency department visit for atrial fibrillation: sex differences in treatment and outcomes in the Global RE-LY AF RegistryLinda S Johnson, Yuxuan Jiang, Judy Luu, et al.
Journal of Thrombosis and Haemostasis : JTH|June 9, 2020
Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trialsJulia Aulin, Ziad Hijazi, Agneta Siegbahn, et al.
The New England Journal of Medicine|May 6, 2005
Amiodarone versus sotalol for atrial fibrillationBramah N Singh, Steven N Singh, Domenic J Reda, et al.
Journal of the American Heart Association|November 27, 2013
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillationBenjamin A Steinberg, Dajuanicia N Holmes, Jonathan P Piccini, et al.
Pageof 19

Showing results (121-130 of 187) with videos related to

Sort By:
Pageof 19
Open Heart|March 20, 2021
Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areasTymon Pol, Ziad Hijazi, Johan Lindbäck, et al.
Stroke|February 3, 2009
Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigatorsCarl van Walraven, Robert G Hart, Stuart Connolly, et al.
Journal of the American College of Cardiology|June 13, 2015
Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY TrialMichael Böhm, Michael D Ezekowitz, Stuart J Connolly, et al.
Circulation. Arrhythmia and Electrophysiology|May 27, 2022
Drug Interactions Affecting Oral Anticoagulant UsePhilip L Mar, Rakesh Gopinathannair, Brooke E Gengler, et al.
Journal of the American College of Cardiology|February 18, 2011
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelinesL Samuel Wann, Anne B Curtis, Kenneth A Ellenbogen, et al.
Circulation|March 8, 2013
Genetic determinants of dabigatran plasma levels and their relation to bleedingGuillaume Paré, Niclas Eriksson, Thorsten Lehr, et al.
European Heart Journal|June 4, 2024
Emergency department visit for atrial fibrillation: sex differences in treatment and outcomes in the Global RE-LY AF RegistryLinda S Johnson, Yuxuan Jiang, Judy Luu, et al.
Journal of Thrombosis and Haemostasis : JTH|June 9, 2020
Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trialsJulia Aulin, Ziad Hijazi, Agneta Siegbahn, et al.
The New England Journal of Medicine|May 6, 2005
Amiodarone versus sotalol for atrial fibrillationBramah N Singh, Steven N Singh, Domenic J Reda, et al.
Journal of the American Heart Association|November 27, 2013
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillationBenjamin A Steinberg, Dajuanicia N Holmes, Jonathan P Piccini, et al.
Pageof 19